| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.9 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | -0.0081 | 0.9 |
| mRNA | Pazopanib | FIMM | pan-cancer | AAC | 0.022 | 0.9 |
| mRNA | AS601245 | GDSC1000 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | darinaparsin | CTRPv2 | pan-cancer | AAC | 0.0082 | 0.9 |
| mRNA | tubastatin A | CTRPv2 | pan-cancer | AAC | -0.0084 | 0.9 |
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |